MODERATO is a phase III, open-label, randomized, multicenter, non-inferiority trial conducted
in West and Central Africa (Cameroon, Côte d'Ivoire, Burkina Faso).
HIV-1 infected adults receiving first line ART with TDF+XTC+EFV virologically suppressed will
be recruited and followed during 100 weeks.
The objective is to assess the non-inferiority of a strategy consisting of switching to a
dual maintenance therapy (DTG+ 3TC or ATV/r+3TC), comparing to WHO standard first line
regimen (TDF+3TC+EFV), in terms of virological success at 96 weeks
Phase:
Phase 3
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)